Indeed, the PKC-DRS2 group subsequently studied this latter effect in more detail and concluded that ruboxistaurin reduces the occurrence of SMVL by 40% in patients with moderately severe to very severe nonproliferative diabetic retinopathy, while increasing the likelihood of visual improvement by a factor of two [66]. Here, PRRT2 is linked to diabetic retinopathy.